Epigral Ltd
Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals.[1]
- Market Cap ₹ 5,030 Cr.
- Current Price ₹ 1,163
- High / Low ₹ 2,114 / 806
- Stock P/E 15.3
- Book Value ₹ 515
- Dividend Yield 0.43 %
- ROCE 15.5 %
- ROE 16.0 %
- Face Value ₹ 10.0
Pros
Cons
- Tax rate seems low
- Debtor days have increased from 42.4 to 60.2 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE Commodities BSE 1000
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 829 | 1,551 | 2,188 | 1,929 | 2,550 | 2,527 | |
| 567 | 1,041 | 1,499 | 1,448 | 1,839 | 1,961 | |
| Operating Profit | 261 | 509 | 689 | 481 | 711 | 566 |
| OPM % | 32% | 33% | 31% | 25% | 28% | 22% |
| 2 | 4 | 8 | 7 | 16 | 15 | |
| Interest | 29 | 44 | 66 | 73 | 53 | 72 |
| Depreciation | 74 | 86 | 109 | 124 | 133 | 168 |
| Profit before tax | 161 | 383 | 522 | 291 | 541 | 341 |
| Tax % | 37% | 34% | 32% | 33% | 34% | 3% |
| 101 | 253 | 353 | 196 | 358 | 332 | |
| EPS in Rs | 24.48 | 60.84 | 85.03 | 47.14 | 82.91 | 76.95 |
| Dividend Payout % | 0% | 0% | 6% | 11% | 7% | 6% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 25% |
| 3 Years: | 5% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | -2% |
| TTM: | -8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 8% |
| 1 Year: | -37% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 18% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 42 | 42 | 42 | 42 | 43 | 43 |
| Reserves | 432 | 684 | 1,028 | 1,213 | 1,861 | 2,178 |
| 753 | 993 | 879 | 964 | 593 | 572 | |
| 222 | 405 | 484 | 576 | 655 | 712 | |
| Total Liabilities | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 | 3,505 |
| 1,102 | 1,068 | 1,804 | 1,767 | 2,238 | 2,117 | |
| CWIP | 126 | 589 | 158 | 483 | 64 | 451 |
| Investments | 0 | 0 | 21 | 21 | 98 | 23 |
| 221 | 467 | 450 | 524 | 752 | 915 | |
| Total Assets | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 | 3,505 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 229 | 284 | 626 | 398 | 441 | 436 | |
| -197 | -455 | -437 | -401 | -262 | -355 | |
| -32 | 195 | -200 | -8 | -164 | -94 | |
| Net Cash Flow | 1 | 24 | -11 | -11 | 15 | -14 |
| Free Cash Flow | 32 | -172 | 210 | -1 | 254 | 50 |
| CFO/OP | 99% | 68% | 106% | 93% | 78% | 90% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 52 | 60 | 28 | 34 | 33 | 60 |
| Inventory Days | 51 | 74 | 69 | 90 | 105 | 89 |
| Days Payable | 69 | 42 | 36 | 63 | 50 | 66 |
| Cash Conversion Cycle | 34 | 92 | 61 | 61 | 88 | 83 |
| Working Capital Days | -92 | -26 | -41 | -54 | 26 | 16 |
| ROCE % | 29% | 32% | 17% | 25% | 15% |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Installed Manufacturing Capacity (Chlor-Alkali + Derivatives) KTPA |
|
|||||||||
| Wind-Solar Hybrid Power Plant Capacity MW |
||||||||||
| Plant Capacity Utilization % |
||||||||||
| Revenue Mix - Derivatives & Specialty Chemicals % |
||||||||||
| Captive Chlorine Consumption % |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Epigral Limited''s Reply To Clarification Sought With Reference To Movement In Volume.
2d - Epigral says volume and share price movement is market-driven, with no undisclosed material information.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - Epigral Limited has informed about Conference Call on Monday, 27th July, 2026 to discuss Q1 FY27 Results
-
Clarification sought from Epigral Ltd
2d - Exchange has sought clarification from Epigral Ltd on July 22, 2026, with reference to Movement in Volume.
-
Board Meeting Intimation for Intimation Of The Board Meeting Of Epigral Limited Scheduled To Be Held On Monday, 27Th July, 2026.
2d - Board meets 27 July 2026 to approve Q1 FY27 standalone and consolidated results.
-
Announcement under Regulation 30 (LODR)-Credit Rating
14 Jul - CRISIL reaffirmed Epigral’s ratings: AA/Stable and A1+ on Rs 1,050 crore bank facilities.
Annual reports
Concalls
-
May 2026Transcript PPT
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
Apr 2024Transcript PPT
-
Apr 2024Transcript PPT REC
-
Apr 2024TranscriptAI SummaryPPT
-
Jan 2024TranscriptPPT
-
Jan 2024Transcript PPT REC
-
Jan 2024TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptAI SummaryPPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptAI SummaryPPT
-
Apr 2023Transcript PPT REC
-
Jan 2023Transcript PPT
-
Jan 2023TranscriptAI SummaryPPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptAI SummaryPPT
-
Jun 2022TranscriptAI SummaryPPT
-
Apr 2022Transcript PPT
-
Apr 2022TranscriptAI SummaryPPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Nov 2021TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Oct 2021TranscriptAI SummaryPPT
-
Aug 2021TranscriptAI SummaryPPT
-
Aug 2021TranscriptAI SummaryPPT
Product Segments[1]
a. Derivatives & Speciality Chemicals (52% in FY26 vs 25% in FY22):[2] The company is the 6th largest producer of Chloromethanes (CMS) in India, its CMS portfolio includes MDC, Chloroform, and CTC. It is also the 5th largest producer of Hydrogen Peroxide in India. It also produces specialty chemicals like CPVC Resin, CPVC compound, Epichlorohydrin, Chlorotoluenes Value Chain, etc. [3]